



PATENT  
Attorney Docket No.: UCSF1100-3

#10  
5/5/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Farinas, Javier Art Unit: 1644  
Application No.: 09/403,882 Examiner: Huynh, P.  
Filed: March 20, 2000  
Title: METHODS AND REAGANTS FOR TARGETING ORGANIC  
COMPOUNDS TO SELECTED CELLULAR LOCATIONS

Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO NOTICE TO COMPLY**

**WITH SEQUENCE LISTING REQUIREMENTS UNDER 37 C.F.R. §§ 1.821-1.825**

Dear Sir:

In response to the notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures mailed March 21, 2001, Applicant provides herewith a computer readable and a paper copy of the Sequence Listing in accordance with 37 C.F.R. § 1.821 *et seq.*

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>4-23-01</u> , in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.	
Rachel Carter	
Name of Person Mailing Paper	
<u>Rachel Carter</u>	<u>4-23-01</u>
Signature	Date

In re Application of: Farinas, Javier  
Application No.: 09/403,882  
Filed: March 20, 2000  
Page 2

PATENT  
Attorney Docket No.: UCSF1100-3

If the Examiner would like to discuss the attached sequence listing, Applicants' representative can be reached at (858) 677-1456.

Respectfully submitted,

Date: 4/23/01



Lisa A. Haile, Ph.D.

Reg. No. 38,347

Telephone: (858) 677-1456

Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1600  
San Diego, CA 92121-2189

USPTO Customer Number: 28213



PATENT  
Attorney Docket No.: UCSF1100-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Farinas, Javier  
Application No.: 09/403,882  
Filed: March 20, 2000  
Title: METHODS AND REAGENTS FOR TARGETING ORGANIC  
COMPOUNDS TO SELECTED CELLULAR LOCATIONS

Art Unit: 1644  
Examiner: Huynh, P.

Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT UNDER 37 C.F.R. §§ 1.821(f) and (g);  
and 37 C.F.R. § 1.825 (b)**

Sir:

I hereby state, as required by 37 C.F.R. § 1.821(f), that the information recorded in computer readable form is identical to the written sequence listing.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821 (g), herein does not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. § 1.825 (b), is the same as the amended Sequence Listing.

Respectfully submitted,

Date: 4/23/01

Lisa A. Haile, Ph.D.  
Reg. No. 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1600  
San Diego, CA 92121-2189

Customer Number: 28213

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>4-23-01</u> , in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.	
Rachel Carter	
Name of Person Mailing Paper	
<u>Rachel Carter</u>	<u>4-23-01</u>
Signature	Date



Applicant:  
Application No.:  
Filed:  
Title:

Farinas, Javier  
09/403,882  
March 20, 2000  
METHODS AND REAGENTS FOR  
COMPOUNDS TO SELECTED CELL

Attorney Docket No.: UCSF1100-3

MARK OFFICE

ORGANIC  
IONS

Commissioner for Patents  
Washington, D.C. 20231

**VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(d)**


Sir:  
I, Mikhail Bayley, declare that I personally prepared the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

*Mikhail Bayley*  
Mikhail Bayley

Date: 04/20/2001  
GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1600  
San Diego, CA 92121-2189  
Customer Number: 28213

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>4-23-01</u> , in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.	
Name of Person Mailing Paper	<u>Rachel Carter</u>
Signature	<u>Rachel Carter</u>
Date	<u>4-23-01</u>



**COPY**

Application No.: **09/403,882**

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**